In 2022, Empyrean achieved a groundbreaking milestone by acquiring Morpheus™, a cutting-edge robotically assisted platform for Brachytherapy and Intraoperative Radiotherapy (IORT). Its versatility, mobility, advanced imaging capabilities, and minimal shielding requirements have generated significant enthusiasm and facilitated vital partnerships with cancer centers across the country.

What truly distinguishes Morpheus™ is its exceptional adaptability, offering energy options ranging from 50-120kV (WIP) and featuring innovative beam sculpting technology. With its precision robotic arm, Morpheus™ stands as a powerful ally in the fight against cancer, enhancing treatment precision and patient outcomes.

Building on this foundation, the Empyrean team is actively enhancing Morpheus™ to better meet the clinical needs of future cancer care. Morpheus™ is set to be submitted for FDA approval and clearance from other global regulatory bodies, expanding its applications across a wide range of lesions, tumors, and conditions where precision radiation is indicated.

“Morpheus 2.0 is not currently for sale. Upon completion of the design, Morpheus™ 2.0 will soon be submitted to the FDA. For any inquiries relating to this product, please contact Empyrean’s research and development department.”

Delivers a Modern Workflow
• Integrated, cloud-based TPS *
• Minimal set-up; no internal shielding
• Rapid dose delivery; < 20 mins total workflow
• Automated robotic source insertion/extraction
• Minimized time under anesthesia
• ZeroGTM floating treatment head manipulation
• Robotically assisted system physics
• Compact. Fits through a standard door
• Mobile with a self-propulsion system

Increases Therapeutic Value
• Integrated tomosynthesis imaging *
• Patented beam forming technology
• Precise target volume definition, avoiding organs at risk
• Modulate energy 50-100kV for depth *
• FLASH capable (>70 Gy/sec) *
• RespiraTrackTM respiratory motion tracking
• Immediate post-operative treatment prior to
additional adjuvant therapies

Unlocks New Treatment Possibilities
• Design unlocks new possibilities for breast, colorectal, liver, spine, and vaginal RT treatment
• Our community of world class luminaries will advance treatment protocols

RAPID
Integrated, cloud-based treatment planning*, no internal shielding, and beam delivery in seconds truly modernizes IORT.

DIRECTIONAL
Highly precise, patented beam-sculpting technology with rapid delivery capability. Ability to spare healthy tissue and organs at risk, while providing a therapeutic dose.

CONFORMAL
On-board tomosynthesis * ensures uniform tissue conformance with treatment depths ranging from 50kV-100kV *.